Allergan has been granted a positive opinion on its drug Botox as a potential treatment for urinary incontinence among patients with multiple sclerosis or spinal cord injury in Europe.
The Irish Medicines Board has recommended the product for management of the condition among adults with neurogenic detrusor overactivity resulting from neurogenic bladder issues, based on positive data from phase III clinical trials.
Following this decision, Allergan will be able to progress with its efforts to secure national licences in the 14 European countries involved in the Mutual Recognition Procedure.
According to Douglas Ingram, president of Allergan in Europe, Africa and the Middle East, the drug will help patients to benefit from improved daily functioning and a better quality of life.
"Our task now is to work closely with the national health authorities to secure the relevant national licences so that we can bring this valuable treatment option to patients," he added.
Last month, Allergan reported its financial results for the second quarter of 2011, during which Botox helped the company to achieve a 13.7 percent year-on-year sales improvement.See all the latest jobs in Pharmaceutical